ABSTRACT Non-adrenergic inhibitory nerves may have an important role in regulating airway calibre. A recently discovered peptide, peptide histidine valine, is a potent relaxer of airway smooth muscle in vitro and has been proposed as a possible neurotransmitter in this tissue. The cardiovascular and respiratory effects of graded infusions of this peptide (2-5-10 pmol kg-' min') have been examined in six normal subjects in a placebo controlled, randomised double blind study. The mean (SEM) peak plasma concentration of peptide histidine valine during the highest infusion rate was 2392 (170) pmol/l, representing a 29 fold increase above the basal concentration. This was accompanied by flushing, a significant increase in heart rate of 28 (3-7) beats/min and skin temperature of 1.80 (0 160) C, but no effect on systolic or diastolic blood pressure. Despite these high plasma concentrations of the peptide and the substantial tachycardia and increase in skin blood flow, there was no change in partial expiratory flow at 40% ofvital capacity (Vp4,) or in the airway response to inhaled histamine (geometric PD40 9*37 and 9 73 umol during saline and peptide histidine valine infusion respectively). Although these findings provide no support for a physiological role of peptide histidine valine in controlling airway function in healthy subjects, important effects oflocally released peptides in the vasoactive intestinal peptide family cannot be excluded. 
Introdoction
Non-adrenergic, non-cholinergic nerves Two subjects (Nos 3 and 6) were studied on a third day in a single blind design with a similar protocol except that they received a higher dose of peptide histidine valine, 20 pmol kg-' min-', which was maintained for 30 minutes. On these two study days the subjects were pretreated with 100 mg atenolol orally four hours before the study to limit cardiovascular side effects, notably the tachycardia. Limited availability ofpeptide histidine valine prevented further studies at this higher dose.
Chilvers, Dixon, Yiangou, Bloom, Ind cardiovascular measurements is shown in figure 3 . The graded infusion caused a progressive increase in heart rate, which reached a maximum of 28 (3-7) beats/min (p < 005) immediately before the histamine challenge. The tachycardia first achieved statistical significance five minutes after the start of the 5 pmol kg' min-' infusion, when the mean plasma peptide histidine valine concentration was 438 pmol/l. The increase in heart rate appeared to plateau with increasing plasma concentrations of the peptide, little further increase occurring with plasma concentrations over 1500 pmol/l. Peptide histidine valine caused a progres- (fig 2) . A significant increase in plasma peptide histidine valine concentration was seen five minutes after the start of the 2-5 and 5*0 pmol kg-' min7' infusion rates (p < 0-05).
The effect of infused peptide histidine valine on the -0.5. histamine. Despite these substantiE rate and skin temperature no chang heart rate and skin temperature but had no effect on systolic or diastolic blood pressure or on airway calibre in these normal subjects. The fall in 'Vp, during the histamine challenge. The geometric mean PD40 histamine was 9-37 .mol (95% confidence interval 5-85-15-01) during the saline infusion and 9 73 umol (6-2-15-26) during the peptide infusion ( fig 5) . This difference was not significant. The two subjects who received peptide histidine valine 20 pmol kg-' min7' had increases of 27% and 24% in Vp4, over baseline values after 15 minutes of this infusion. This compared with no increase and a 13% increase 15 minutes from the start of the 10 pmol kg' min-' infusion on the previous study day. PD,, histamine values were increased from 12-3 and 16-9 umol during the 10 pmol kg-' min-' infusion to 22-5 and 24-3 umol during the 20 pmol kg-' min-' infusion in the two subjects.
Discussion
Infusion ofpeptide histidine valine in doses of up to 10 pmol kg-' min-' caused a dose dependent increase in To examine the possibility that an airway effect might occur with a higher dose of peptide histidine valine, two subjects were studied on a third day with a higher dose, 20 pmol kg-' min-', of infused peptide histidine valine and a similar protocol. Although this study was uncontrolled, the increase in Vp0 and PD., histamine in both subjects suggests that infused peptide histidine valine has the potential, at higher doses, to cause bronchodilatation.
The cardiovascular effects of infused peptide histidine valine in producing a considerable tachycardia and increase in skin temperature, but no change in blood pressure, are intriguing. In this respect the effect of peptide histidine valine is quite distinct from vasoactive intestinal peptide and peptide histidine methionine, which at much lower plasma concentrations, and for the same degrees of change in heart rate and skin temperature, produce substantial falls in diastolic and to a lesser extent in systolic blood pressure.'3 A direct chronotropic effect of peptide histidine valine on the heart has been proposed,'3 but its apparent lack ofeffect on arteriolar resistance while it is dilating skin vessels is unexplained.
The physiological role of peptide histidine valine is uncertain. In addition to its effects on airway smooth muscle in vitro it is a potent relaxer of guinea pig gastric smooth muscle and reduces the force and frequency of spontaneous uterine contractions in the rat.'0 It has been identified in mammalian nasal mucosa, stomach, genitalia, and airways." '5 In man, normal circulating concentrations of the peptide in the resting state are around 80 pmol/l. It is the Chilvers, Dixon, Yiangou, Bloom, Ind major circulating peptide in patients with VIPomas, with concentrations 10 times higher than those of vasoactive intestinal peptide or peptide histidine methionine, and it may be responsible for the profuse diarrhoea and other clinical features seen in patients with these tumours. '6 The possible role of peptide histidine valine as a neurotransmitter of non-adrenergic nerves in airway smooth muscle needs further investigation. Although no significant effect on airway calibre or histamine responsiveness was seen at infusion rates up to 10 pmol kg-' min-', higher doses may result in a small increase in both these measurements. Our study does not rule out an effect of locally released peptide histidine valine. The 
